Publications by authors named "Ayush Peddireddi"
Leuk Lymphoma
October 2024
Article Synopsis
- FDA-approved treatments ruxolitinib and belumosudil are effective as steroid-sparing agents for chronic GVHD with overall response rates of 76% and 65% respectively.
- A study of 20 patients using a combination of these agents showed a 55% overall response rate, helping patients reduce or stop other immunosuppressants without major complications.
- The combination therapy proved tolerable, did not worsen blood cell counts, and successfully postponed the need for more aggressive treatments.
